Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2017

View Archived Issues

Frequency Therapeutics announces closing of series A financing

Inovio Pharmaceuticals reports initial results from phase I study of Ebola vaccine

Appili Therapeutics receives funding from Canadian government to develop antibiotic

FDA grants reactivation status for MARVEL phase II/III trial

Preclinical characterization of the novel adenosine A2A receptor inhibitor AZD-4635

LTT Bio-Pharma reports results of phase II clinical trial for LT-4002

Positive topline results from phase II trial of SB-208

Janssen develops promising tau PET tracer JNJ-067

First patient treated in METROmaJX study of Pexa-Vec

New Alzheimer's disease model uses hearing impairment to assess progression

BioCryst Pharmaceuticals announces plans to test oral liquid formulation of BCX-7353

KNOW Bio Respiratory changes name to Novoclem Therapeutics

Ironshore announces plans for two pivotal studies of HLD-100

First clinical study of gastrin analogue CP-04 as a theranostic for medullary thyroid carcinoma

XOMA tests anti-PTH1R human monoclonal antibodies in vitro and in rodent models

Positive phase III 6-month topline safety and efficacy results from Rocket-4 study of Rhopressa

Araxes Pharma discloses novel RAS family inhibitors

Siemens Healthineers receives HSS funding for the development of novel Zika diagnostic test

Taisho Pharmaceutical patents orexin receptor antagonists

Novel MALT1 inhibitors identified at Toray Industries

Roche launches diagnostic antibody to help distinguish morphologically difficult prostate cancers

Concert Pharmaceuticals discovers new CFTR potentiators

Sichuan Haisco Pharmaceutical discloses new muscarinic receptor antagonists

Jagiellonian University and collaborators patent 5-HT6 receptor antagonists

Shionogi applies for manufacture and sales approval for lisdexamfetamine dimesylate in Japan

GlaxoSmithKline initiates first-in-human trial of GSK-3036656

Patient enrollment begins in phase III AURORA trial of cenicriviroc

Mayo Clinic initiates phase I trial of VSV-hIFNbeta-NIS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...